Key Cases in EU Competition Law Analysis | Quizlet

Metro v Commission

The key legal issue was whether the European Commission's decision to grant an exemption under Article 85(3) of the EEC Treaty to SABA's selective distribution system was lawful.

Article 85(1)

Prohibits agreements between undertakings that may affect trade between Member States and that prevent, restrict, or distort competition within the common market.

Article 85(3)

Allows exemptions from the prohibition if the agreement contributes to improving the production or distribution of goods, promotes technical or economic progress, allows consumers a fair share of the resulting benefit, does not impose unnecessary restrictions, and does not eliminate competition for a substantial part of the market.

SABA's selective distribution system

A system that imposed restrictive conditions, such as prohibitions on direct sales to institutional consumers and turnover requirements for wholesalers.

Metro's claim

Metro claimed that SABA's selective distribution system unjustly excluded it from the market.

Court's evaluation

The Court evaluated whether the conditions imposed by SABA were indispensable to achieving the goals of improved distribution and technical progress.

Proportionality of restrictions

The Court emphasized that restrictions on competition must be proportionate and necessary to achieve objectives of improved distribution and product quality.

European Court of Justice ruling

The Court upheld the Commission's decision, ruling that the selective distribution system did not violate Article 85(1) when considered alongside the exemption criteria in Article 85(3).

GlaxoSmithKline v Commission

The primary issue revolves around whether GSK's agreement with Spanish wholesalers, which imposed differential pricing to limit parallel trade of pharmaceuticals within the EU, violated Article 81(1) EC.

Article 81(1) EC

Prohibits agreements between undertakings that restrict competition within the internal market, particularly those that aim to prevent, restrict, or distort competition.

Article 81(3) EC

Exemptions are possible if the agreement contributes to improving the production or distribution of goods or promotes technical or economic progress while allowing consumers a fair share of the benefits.

GSK's dual pricing scheme

Implemented a scheme with lower prices for drugs sold domestically within Spain and higher prices for those intended for export to other EU Member States.

Commission's finding

The Commission found GSK's agreement restrictive as it aimed to curtail parallel trade, thereby limiting intra-EU competition.

Court of First Instance support

The Court supported GSK's position to some extent, stating that the legal and economic context did not automatically imply an anti-competitive effect.

Court of Justice emphasis

The Court of Justice emphasized that Article 81(1) EC protects the competitive structure of the market, not just consumer welfare.

Parallel Trade

Agreements that aim to limit parallel trade can be inherently restrictive of competition, even without direct consumer harm.

Article 81(1) EC

Prohibits agreements between undertakings that prevent, restrict, or distort competition within the internal market.

Groupement des cartes bancaires (CB) v European Commission

A case concerning whether pricing measures by CB constituted a restriction of competition 'by object' under Article 81(1) EC.

Restrictions by Object

Some types of coordination (e.g., horizontal price-fixing cartels) are so harmful to competition that they are considered restrictions by object.

Determining Restrictions by Object

To determine if an agreement restricts competition by object, courts consider its provisions, objectives, and the economic and legal context.

Economic and Legal Context

The economic and legal context of an agreement is one of the factors considered to determine if it restricts competition by object.

Parties' Intentions

The parties' intentions may be considered but are not required to determine if an agreement restricts competition by object.

CJEU Ruling

The Court of Justice (CJEU) overturned the General Court's decision, stating that not all practices that restrict competition automatically qualify as restrictions by object.

General Court's Judgment

The General Court failed to apply the correct legal standard for determining a restriction 'by object' in the CB case.

Anti-competitive Effect

For measures to be classified as restrictive 'by object', they must reveal a sufficient degree of harm to competition.

Pricing Measures

The measures adopted by CB included fees for new entrants and mechanisms regulating card-issuing activities.

Market Capacity Agreements

The Court criticized the General Court for improperly equating CB's measures with cases like BIDS, where the anti-competitive harm was clear-cut.

Internal Objectives

The General Court relied heavily on the internal objectives behind CB's rules and the intentions of its main members.

Conclusion of CJEU

The CJEU set aside the General Court's judgment, ruling that CB's measures could not be classified as restrictive 'by object' without a deeper assessment.

Conclusion of GSK's Appeal

The Court ultimately dismissed GSK's appeal, confirming that the agreement infringed Article 81(1) EC.

Commission's Reasoning

While some parts of the Commission's reasoning were criticized, the restriction of parallel trade was found to have an anti-competitive object.

Exemption under Article 81(3) EC

GSK's request for an exemption under Article 81(3) EC was rightly rejected.

French Payment Card Market

The measures were alleged to limit competition, particularly for new entrants in the French payment card market.

Actual Effects on Competition

If the coordination does not clearly reveal such harm, its actual effects on competition must be examined.

Content of the Agreement

The content of the agreement is one of the factors considered to establish a restriction 'by object'.

Healthy competition

The nucleus of capitalist economies that drives innovation and benefits consumers.

SCP thinking

A framework for analyzing competition through Structure, Conduct, and Performance.

EU competition law

Regulations governing competition within the European Union to ensure fair market practices.

101 TFEU

Prohibition of cooperation that restricts competition.

102 TFEU

Prohibition of abuse of dominance by companies in the market.

106 - 109 TFEU

Rules for member states regarding competition, particularly in relation to state aid.

Merger control

Prior approval required for significant mergers and takeovers to prevent anti-competitive practices.

Internal market

A market characterized by free movement of goods and services, requiring undistorted competition.

Protocol No. 27

Addresses the objective of competition in creating an internal market free from barriers.

Price fixing

An illegal practice where businesses agree on prices, undermining competition.

Reverse engineering in competition law

A method to identify the objectives of EU competition law by analyzing its impacts.

Market structure

The organization of a market, including the number and size of firms.

Market conduct

The behavior of firms in the market, including pricing and marketing strategies.

Market performance

The outcomes of market activities, such as efficiency and consumer welfare.

Art. 102

Article that sanctions practices harming competition and consumers, directly or indirectly.

Intel case

A legal case illustrating that not all market exits indicate abusive conduct; some reflect healthy competition.

Consumer healthcare

A critical aspect of competition law that can justify competitively restrictive behavior.

Accused undertaking

The company or entity accused of violating competition law.

Commission

The body acting on a complaint regarding competition law violations.

Plaintiff

The party bringing a complaint or legal action in a competition law case.

Servizio case

A case that clarifies that competition law does not preclude market exits of less efficient competitors.

Barriers to trade

Obstacles that prevent free movement of goods and services between member states.

Competition rules

Regulations designed to maintain fair competition and prevent market distortions.

Competition

The relation between competitors and competition/the competitive process; competition can exist without competitors if barriers to entry are low.

Market Structure

The relation between market structure and the competitive process.

Competitive Process and Efficiency

The competitive process's outcome, known as performance, is better assessed by looking at company performance rather than just market structure.

Selective Distribution

A practice that solidifies the market by reducing the number of distributors, leading to higher market power and uniform, higher prices.

GlaxoSmithKline Case

Illustrates that pharmaceutical companies often have a market monopoly due to government patents, allowing them to charge higher prices.

Monopoly

A monopoly is not inherently problematic if it delivers quality and innovation.

Consumer Welfare Trade-off

The balance between current consumer welfare and future consumer welfare, where higher prices may fund innovation.

Cartes Bancaires Case

Highlights that consumer welfare is only one aspect of competition law, as the system's collapse could revert the market to cash-based.

Commission Guidance

States that complaints can only be made by efficient competitors, which may exclude small competitors from EU competition law protection.

Quantifying Consumer Welfare

Consumer welfare is quantified through prices and quality of products or performance.

Error Costs in Digital Markets

Refers to the costs associated with false negatives and false positives in competition law enforcement.

False Positive (Type I Error)

Occurs when a pro-competitive practice is incorrectly classified as anti-competitive.

False Negative (Type II Error)

Happens when an anti-competitive practice is mistakenly considered legal or harmless.

False Positive Example

A new pricing strategy that benefits consumers is mistakenly seen as price-fixing.

False Negative Example

A dominant platform engages in self-preferencing, but authorities fail to act.

Impact of False Positives

Discourages innovation and efficiency as companies fear legal action for beneficial practices.

Impact of False Negatives

Allows monopolistic behavior, harming competition and consumers by reducing choices and increasing prices.

Digital Distribution

Includes digital markets, which can lead to the closure of real shops.

Competition and Fairness

More competition does not necessarily mean more fairness for consumers.

Consumer Choice in Browsers

Offering many browser options may still lead to dominance by a few, like Google or Safari.

Pharmaceutical Market Dynamics

Higher prices in pharma are influenced by consumer fear of death, allowing companies to maintain monopolies.

Market Monopoly

Pharmaceutical companies often maintain monopolies through patents, affecting pricing.

Innovation Funding

Higher prices can fund innovation and the development of new drugs.

EU Competition Law

Not solely focused on consumer welfare but also on protecting the integrity of the market structure.